ClinicalTrials.gg
CompletedNCT01084889Updated Feb 4, 2019

Anterior Pelvic Prolapse Reconstruction With TiLOOP® Total 6

An observational study in Cystocele and Uterine Prolapse, sponsored by pfm medical gmbh. Completed at 9 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-04.

Sponsored by pfm medical gmbh · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
292
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to determine the influence of Anterior Pelvic Prolapse Reconstruction with a titanised polypropylene mesh on rate of erosion and patients quality of live.

Read the detailed description

This multicentre, non-randomised, observational clinical device investigation will be performed to obtain post-marketing information on the TiLOOP® pelvic floor reconstruction meshes and in particular on the rate of rare erosions of the device under investigation as well as on the improvement of patients' quality of life. It is expected that the rate of erosions is equal or lower compared to competitor devices currently on the market. To verify this, it will be shown that within the first year the erosion rate found for the product under investigation is in the range of 7.9 ± 5.4 %, which is the mean erosion rate found in the recent literature. Erosion, in the sense of the hypothesis, is any erosion 1 requiring more than simply the cut off of a single short filament.

It is also expected that the patient's quality of life is meliorated after implantation of a TiLOOP® Total 6 mesh. To verify this, it will be shown that by means of a validated questionnaire the subjective quality of life after 6 months is significantly better than before implantation.

02

Conditions studied

  • Cystocele
  • Uterine Prolapse

Keywords

  • polypropylene mesh
  • Prolapse
  • Cystocele
  • Surgical Mesh
03

In context

Cystocele

71 studies on the registry are indexed under Cystocele; 5 are open to participants now.

This study's enrollment of 292 is close to the median of 292 across 23 observational studies indexed under Cystocele.

Browse Cystocele studies →

Lead sponsor

pfm medical gmbh is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women with a symptomatic genital descensus treated in the center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with a symptomatic genital descensus : at least stage II (ICS-classification according POP-Q system), or stage I with a symptomatic requiring intervention. This applies to primary as well as recurrent intervention
  • Existence of a cystocele.
  • Patient is mentally able to understand the nature, aims, or possible consequences of the clinical investigation
  • Patient information has been handed out and all written consents are at hand.
  • Patient has attained full age.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or unfinished family planning.
  • Known intolerance to the mesh-implants under investigation.
  • Patients with acute (last 12 months) carcinoma.
  • Patients with history of radiotherapy in the pelvic area.
  • Genital descensus without any complaints.
  • Patients with implanted pelvic floor mesh.
  • Systemic treatment.
  • Lack of written patients' .
  • Lack of patient compliance regarding data collection, treatment or follow-up investigations in the scope of the protocol.
  • Patient is institutionalised by court or official order (MPG §20.3).
  • Participation in another clinical investigation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
292 participants (actual)

Groups and cohorts

  • symptomatic genital descensus

    Women with a symptomatic genital descensus : at least stage II (ICS-classification according pelvic organ prolapse quanification (POP-Q) system), or stage I with a symptomatic requiring intervention. Standard method to implant the TiLOOP® Total 6 surgical mesh transvaginally.

    Device: surgical mesh implantation (TiLOOP® Total 6)

Interventions

  • Devicesurgical mesh implantation (TiLOOP® Total 6)

    The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The surgical mesh TiLOOP® Total 6 is placed transvaginal by the aid of TiLOOP® surgical instruments to place the mesh arms.

    Also known as: TiLOOP® Total 6

06

What researchers measure

Primary outcomes

  1. Erosion rate

    Erosion, in the sense of the end point, is any erosion requiring more than simply the cut off of a single short filament.

    Time frame: 12 months

  2. Patient's quality of life

    It will be shown that by means of a validated questionnaire whether the subjective quality of life after 6 months is significantly better than before implantation.

    Time frame: 6 months

Secondary outcomes

  1. Adverse Events

    Documentation and independent evaluation of all complications.

    Time frame: at 6, 12, 36 months

  2. Feasibility of the mesh implantation

    Evaluation of questions on usability.

    Time frame: 6 months

  3. Erosion rate

    Erosion, in the sense of the end point, is any erosion requiring more than simply the cut off of a single short filament.

    Time frame: 36 months

  4. Patient's quality of life

    It will be shown that by means of a validated questionnaire whether the subjective quality of life after 6 months is significantly better than before implantation.

    Time frame: 12 and 36 months

07

Study locations

9 sites
  • Berliner Kontinenzzentrum am Franziskus Krankenhaus,
    Berlin, 10787, Germany
  • Krankenhaus Dresden- Friedrichsstadt
    Dresden, 01067, Germany
  • Evangelisches Diakoniekrankenhaus Freiburg
    Freiburg, Germany
  • Universitätsklinikum Eppendorf
    Hamburg, 20246, Germany
  • St. Elisabeth Krankenhaus Leipzig,
    Leipzig, 04277, Germany
  • Regionale Kliniken Holding RKH GmbH, Klinikum Ludwigsburg
    Ludwigsburg, 71640, Germany
  • Beckenbodenzentrum München
    München, 81679, Germany
  • Klinik Tettnang GmbH
    Tettnang, 88069, Germany
  • Klinikum Oberlausitzer Bergland gGmbH,
    Zittau, 02763, Germany
08

References and documents

Publications

  • Farthmann J, Mengel M, Henne B, Grebe M, Watermann D, Kaufhold J, Stehle M, Fuenfgeld C. Improvement of pelvic floor-related quality of life and sexual function after vaginal mesh implantation for cystocele: primary endpoint of a prospective multicentre trial. Arch Gynecol Obstet. 2016 Jul;294(1):115-21. doi: 10.1007/s00404-016-4014-0. Epub 2016 Jan 18. PubMed 26781262 ↗
  • Funfgeld C, Stehle M, Henne B, Kaufhold J, Watermann D, Grebe M, Mengel M. Quality of Life, Sexuality, Anatomical Results and Side-effects of Implantation of an Alloplastic Mesh for Cystocele Correction at Follow-up after 36 Months. Geburtshilfe Frauenheilkd. 2017 Sep;77(9):993-1001. doi: 10.1055/s-0043-116857. Epub 2017 Sep 25. PubMed 28959063 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2010 to primary completion in Jan 2014, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2010
First posted
Mar 11, 2010
StartActual
Apr 2010
Primary completionActual
Jan 2014
CompletionActual
Jun 2016
Last update
Feb 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01084889
Lead sponsor
pfm medical gmbh
Collaborators
Aix Scientifics, GfE Medizintechnik GmbH, pfm medical titanium gmbh, Bayes GmbH, Crolll Gmbh
Responsible party
Sponsor
First posted
Mar 11, 2010
Start date
Apr 2010
Primary completion
Jan 2014
Completion
Jun 2016
Last update
Feb 4, 2019

Study contacts

Christian Fünfgeld, Dr. MD
principal investigator · Klinik Tettnang GmbH, Tettnang

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion